27 results on '"Masetti C."'
Search Results
2. Emerging metabolic and alcoholic etiologies in liver cirrhosis are related to high rate of recurrence after first episode of decompensation
3. Identification of key predictors of significant weight loss in metabolic dysfunction-associated steatotic liver disease (MASLD) patients: a multicentre study
4. High Incidence of sepsis caused by MDR bacteria in patients undergoing Percutaneous biliary drainage for the treatment of biliary obstruction
5. Myosteatosis is not associated with complications or survival in HCC patients undergoing transarterial embolization
6. Prevalence and predictiors of porto-sinusoidal vascular disorder in patients with constantly elevated gamma-glutamyl transferase levels: A multicenter Italian study
7. High rates of histological findings compatible with porto-sinusoidal vascular liver disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy
8. No impact of the 2020 COVID-19 lockdown on hospitalization rates for alcoholic liver disease in a large tertiary hospital in Milan
9. High prevalence of multiple drug resistant bacterial infections in patients with pyogenic liver abscesses following loco regional therapy for liver cancer
10. Sarcopenia is common in patients with cirrhosis and unresectable HCC treated by transarterial embolization but is not associated with increased rates of complications
11. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen
12. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance
13. Overall survival and incidence of liver-related events in a cohort of cirrhotic patients treated with direct antiviral agents: results from a multicenter study
14. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience
15. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis
16. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy
17. Decreased alpha-fetoprotein levels in HCV cirrhotic patients after direct-acting antiviral agents therapy. Does this indicate a reduced risk of hepatocellular carcinoma?
18. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life
19. Natural HCV resistance is common in Italy and differently associated to genotypes
20. Treatment with direct-acting antiviral agents is associated with improvement of renal function in a cohort of HCV-infected patients with chronic kidney disease
21. Liver stiffness and portal hypertension predict failure to DAA treatment in a real-life cohort of HCV-infected patients treated with recommended regimens
22. Multiclass HCV resistance to interferon-free direct acting antivirals regimens in real life failures advocates for tailored second-line therapies
23. The challenge of HCV-retreatment after DAA-failure: Italian real-life from VIRONET-C network
24. Clinical and functional changes associated with the sustained virological response after treatment of genotype-1 HCV recurrence in liver transplant recipients: Does sofosbuvir differ from peg-interferon based therapy?
25. Treatment failure to first-line direct antiviral (DAA) in HCV-related advanced liver disease: An Italian real-life urban setting
26. Cryptogenic cirrhosis is associated with cardiometabolic and oncologic comorbidities and poor liver-related prognosis
27. Should individuals who have been cured of hepatitis C virus and their partners be allowed to donate blood?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.